SCHEMBL3261271

SCHEMBL3261271

CC(C)n1ncc2cc(C=O)c(-c3ccsc3)nc21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 5/20 0.36
KDM5B Q9UGL1 1/20 0.36
RET P07949 1/20 0.34
PIK3CD O00329 2/20 0.33
ABL1 P00519 2/20 0.33
EGFR P00533 2/20 0.33
HCK P08631 2/20 0.33
SRC P12931 2/20 0.33
KDR P35968 2/20 0.33
PIK3CA P42336 2/20 0.33
MTOR P42345 2/20 0.33
PIK3CG P48736 2/20 0.33
EPHB4 P54760 2/20 0.33
PRKDC P78527 2/20 0.33
PIK3CB P42338 1/20 0.33
TP53 P04637 3/20 0.32
GAA P10253 3/20 0.32
MAPT P10636 3/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
CYP2A6 P11509 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13954524 0.75 KDM4E (0.38) PIK3CDABL1EGFRHCKSRC
SCHEMBL3262284 0.72 CYP1A2 (0.43) PIK3CDABL1EGFRHCKSRC
SCHEMBL3261364 0.71 GPBAR1 (0.62)
SCHEMBL3262450 0.71 GPBAR1 (0.46)
SCHEMBL13492814 0.71 GPBAR1 (0.50)
SCHEMBL3262682 0.69 CSNK2A2 (0.46) ERN1CYP2A6NPC1
SCHEMBL1880359 0.68 KDR (0.48) ERN1KDRTP53GAAMAPT
SCHEMBL4742392 0.66 BACE1 (0.46) ERN1KDRADORA3MEN1KMT2A
SCHEMBL4740926 0.66 GPBAR1 (0.59) ERN1KDM4ENPC1ALDH1A1KMT2A
SCHEMBL1694883 0.65 KDM4E (0.58) KDM5BRETADORA3ADORA2AADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010016846-A1 HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2010-02-11 WO disclosed
WO-2010016846-A1 HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2010-02-11 WO disclosed
US-20090054304-A1 HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-02-26 US disclosed
US-20090054304-A1 HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-02-26 US disclosed
US-20090054304-A1 HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054304-A1 HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE GPBAR1, GPR119, PLAAT5 ERN1 2319/4885KDM5B 2116/4885RET 1534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.